2026 European Sleep Apnea Guidelines: What the Latest ERS and National Updates Changed for Patients
The 2026 European sleep apnea guidelines update, explained for patients
Europe is moving toward home testing, more non-CPAP choices, and earlier care for mild cases. Here is what actually changed for you.
What the 2026 European sleep apnea guidelines update really means
The 2026 European sleep apnea guidelines update is best understood as a shift toward patient choice, home-based testing, and earlier, lighter-touch care for milder disease. European bodies have not torn up the rulebook. Instead, they keep building on the European Respiratory Society (ERS) framework while national systems in the UK, France, and Germany translate it into the everyday care you actually receive.
Obstructive sleep apnea (OSA) means your throat repeatedly narrows or closes during sleep, briefly stopping your breathing. The 2026 European sleep apnea guidelines update matters because it widens the menu of guideline-backed options beyond a CPAP mask, especially for mild-to-moderate OSA. If you want the bigger picture across every therapy, our complete 2026 sleep apnea treatment guide ranks every option by evidence, and our explainer on why your OSA now needs personalized, endotype-based treatment shows where European thinking is heading next.
The scale is large. Roughly 175 million people in Europe have OSA, and about 90 million have moderate-to-severe disease, defined as 15 or more breathing events per hour (Benjafield et al., The Lancet Respiratory Medicine, 2019). Yet a French population study found only 3.5% of people were treated while 18.1% of untreated participants screened positive (ERJ Open Research, 2023). That undiagnosed gap is exactly what the 2026 direction tries to close.
- The 2026 update emphasizes home diagnosis, telemedicine, and earlier care.
- Non-CPAP options stay front and centre for mild-to-moderate OSA.
- Most Europeans with OSA remain undiagnosed and untreated.
How OSA severity is graded across Europe
OSA severity is measured by the apnea-hypopnea index (AHI), the average number of complete (apnea) and partial (hypopnea) breathing pauses per hour of sleep. This threshold logic drives every recommendation in the 2026 European sleep apnea guidelines update, because the right treatment depends heavily on how severe your disease is.
European and international definitions broadly agree on the bands below. Knowing your AHI band is the single most useful number to bring to any treatment conversation, since it determines which options are appropriate and which are not.
| Severity | AHI (events/hour) | Typical first-line direction |
|---|---|---|
| Normal | Fewer than 5 | Lifestyle, monitor symptoms |
| Mild OSA | 5 to 14 | Non-CPAP options often preferred |
| Moderate OSA | 15 to 29 | CPAP or device, shared decision |
| Severe OSA | 30 or more | CPAP usually first-line |
- AHI of 5 to 14 is mild; 15 to 29 is moderate; 30 or more is severe.
- Severity, symptoms, and preference together guide treatment.
- Milder cases now have more guideline-backed non-CPAP choices.
Diagnosis in 2026: home testing and telemedicine go mainstream
The clearest practical change is how you get diagnosed. Across Europe, assessment is increasingly ambulatory and home-based rather than confined to an overnight lab stay. Primary-care screening tools and home sleep apnea tests now route many patients through a faster, less disruptive pathway in 2026.
Most journeys start with a questionnaire. The Epworth Sleepiness Scale measures how likely you are to doze in everyday situations, while STOP-Bang scores risk factors such as snoring, tiredness, observed pauses, and blood pressure. Sleep-disordered breathing affects up to 20% of the community, and 4 to 5% of middle-aged adults have OSA plus excessive daytime sleepiness (European Respiratory Journal, 2009), so efficient triage matters.
1Screening at primary care
Your GP or sleep service uses Epworth and STOP-Bang to gauge risk before any device is sent home. This filters who needs testing.
2Home sleep apnea testing
A small wearable records airflow, oxygen, and effort overnight in your own bed. It suits most uncomplicated suspected OSA cases.
3Lab study when needed
Full in-lab polysomnography stays reserved for complex cases, suspected central apnea, or when home results are unclear.
- Home sleep testing is now accepted for most uncomplicated OSA cases.
- Questionnaires triage who needs a device study at all.
- Lab polysomnography is reserved for complex or unclear cases.
Non-CPAP options the ERS keeps front and centre
The European stance keeps non-CPAP therapies central for the milder end of the spectrum. The ERS guideline on non-CPAP therapies for OSA recommends custom-made mandibular advancement devices (MADs) for mild-to-moderate OSA and for patients who cannot tolerate CPAP, noting that MADs reduce AHI and daytime sleepiness versus placebo (European Respiratory Review, 2021). The 2026 European sleep apnea guidelines update reinforces, rather than reverses, this preference for choice.
A MAD is a custom dental appliance that holds your lower jaw slightly forward to keep the airway open. It is one of several alternatives. Real-world practice varies widely: in the European Sleep Apnea Database, 65.5% of mild-to-moderate patients received a PAP recommendation and 34.5% a MAD, with MAD use ranging from 0% to 76% across centres (ERJ Open Research / ESADA, 2025). That spread shows how much your location and clinician influence what you are offered.
| Option | Best-fit severity | How it works | Practical notes |
|---|---|---|---|
| CPAP | Moderate to severe | Mask delivers pressurized air | Most effective; tolerance can be hard |
| Mandibular advancement device | Mild to moderate | Holds jaw forward | ERS-preferred alternative; custom fit |
| Positional therapy | Position-dependent OSA | Stops back sleeping | Simple add-on for some patients |
| Myofunctional therapy | Mild OSA, snoring | Tongue and throat exercises | Low cost, needs consistency |
| Back2Sleep nasal stent | Snoring, mild-to-moderate OSA | Soft silicone stent keeps the nasal airway open | CE-certified Class I; no prescription; comfort-first |
This is where a soft intranasal option fits the gap competitors ignore. The 2026 AASM position statement on nasal stents details what officially changed for this device class. The Back2Sleep nasal stent is a CE-certified Class I soft silicone device that keeps the nasal airway open during sleep, with no electricity, noise, or tubing. It is intended for snoring and mild-to-moderate OSA only, not as a CPAP replacement for severe disease, and a proper sleep study should always come first.
- The ERS recommends MADs for mild-to-moderate OSA and CPAP-intolerant patients.
- What you are offered varies enormously between European centres.
- Comfort-first, non-CPAP options suit the milder severity band.
GLP-1 drugs like tirzepatide: the nuance the headlines blur
The most hyped recent change is medication. Tirzepatide gained European Medicines Agency (EMA) approval for moderate-to-severe OSA in adults with obesity after the SURMOUNT-OSA program showed roughly 27 to 30 fewer apnea events per hour at 52 weeks (SURMOUNT-OSA program, 2024). That is a meaningful result, but the detail matters.
This approval is specifically for moderate-to-severe OSA combined with obesity. It is not a shortcut for mild disease, and it is not a stand-alone cure for everyone who snores. European clinicians weigh it as one tool within a weight-and-airway strategy, not as a replacement for a confirmed diagnosis or for established therapies in the appropriate severity band.
- Tirzepatide is approved for moderate-to-severe OSA with obesity, not mild disease.
- Trial data showed about 27 to 30 fewer events per hour at one year.
- It complements, rather than replaces, severity-based treatment.
How the rules cascade through France, Germany, and the UK
European guidance is not a single law you live under. The ERS framework sets the scientific direction, then each national system shapes the pathway, reimbursement, and access you experience in 2026. Knowing your country's logic helps you ask the right questions.
United Kingdom
NICE guidance (NG202) frames the classic triad of loud snoring, witnessed apneas, and daytime sleepiness, using Epworth and STOP-Bang at primary care. It directs CPAP for moderate-to-severe OSAHS and oral appliances such as MADs for mild-to-moderate disease, alongside weight management and driving-safety checks.
France
France runs a strongly reimbursement-driven pathway, with structured diagnosis and follow-up tied to therapy adherence. The large undiagnosed gap shown in French cohort data (ERJ Open Research, 2023) is precisely why earlier screening and home testing are emphasized in 2026.
Germany
Germany combines specialist sleep-lab capacity with expanding ambulatory and home-testing routes, reflecting the same European pull toward less disruptive diagnosis while keeping severe cases in expert hands.
| Region | Lead framework | Mild-to-moderate emphasis |
|---|---|---|
| European (cross-border) | ERS non-CPAP guideline | MADs and alternatives encouraged |
| UK | NICE NG202 | Oral appliances for milder OSAHS |
| France | National reimbursement pathway | Earlier screening, adherence follow-up |
| Germany | Sleep labs plus ambulatory testing | Growing home-test access |
- The ERS sets direction; national systems control access and reimbursement.
- UK, France, and Germany all push milder cases toward earlier, lighter care.
- Ask which pathway and options apply in your specific country.
ERS versus AASM: why European patients should not copy US framing
The ERS and the American AASM guidelines share GRADE methodology and broad goals, but they differ in scope and emphasis. The ERS produced a dedicated non-CPAP therapies guideline that keeps alternatives prominent for mild-to-moderate OSA, while recent AASM work has focused on central sleep apnea and inpatient OSA management.
For a European reader, this matters practically. Your reimbursement, regulators, and pathways are EU-based, so US-only frameworks, payers, and approvals are context at best. The 2026 European sleep apnea guidelines update is the reference that actually governs the care you can access, including the non-CPAP options you may prefer.
- ERS and AASM share methods but differ in focus and scope.
- ERS keeps non-CPAP alternatives central for milder OSA.
- European patients should follow EU, not US, frameworks for access.
What the 2026 European sleep apnea guidelines update means for your next step
The headline for patients is choice. The 2026 European sleep apnea guidelines update gives people with mild-to-moderate OSA more legitimate, less invasive options and faster routes to diagnosis. Severe disease still warrants CPAP first, but the milder band now has real alternatives backed by guidelines.
Start by confirming your diagnosis with a home or lab sleep study and learning your AHI band. Then have a shared-decision conversation about CPAP, oral appliances, positional therapy, and comfort-first nasal options that match your severity. The right choice is the effective one you will actually use every night.
- Get a proper sleep study and learn your AHI band first.
- Match the option to your severity, then to your comfort.
- For mild-to-moderate OSA, you now have more guideline-backed choices.
What Back2Sleep Users Say
Frequently Asked Questions
What changed in the 2026 European sleep apnea guidelines?
The 2026 European direction emphasizes home-based diagnosis, telemedicine triage, and earlier care for milder disease. It keeps non-CPAP therapies central for mild-to-moderate OSA, building on the ERS framework rather than replacing it. The big practical shift is more patient choice and faster, less disruptive routes to assessment and treatment.
What is the difference between the ERS and AASM sleep apnea guidelines?
Both use GRADE methodology but differ in scope. The European Respiratory Society produced a dedicated non-CPAP therapies guideline that keeps alternatives prominent for mild-to-moderate OSA. Recent American AASM work focused more on central sleep apnea and hospitalized patients. European patients should follow EU frameworks, since reimbursement and regulators are EU-based.
Do European guidelines recommend CPAP or a mandibular advancement device for mild sleep apnea?
For mild-to-moderate OSA, the ERS recommends custom-made mandibular advancement devices, and they are often preferred over CPAP for milder cases or CPAP-intolerant patients (European Respiratory Review, 2021). CPAP remains first-line for moderate-to-severe disease. Your final choice depends on AHI, symptoms, and personal preference through shared decision-making.
Is home sleep apnea testing now accepted under European guidelines?
Yes. Across Europe, diagnosis is increasingly ambulatory and home-based for most uncomplicated suspected OSA. A small wearable records airflow, oxygen, and effort in your own bed. Full in-lab polysomnography is reserved for complex cases, suspected central apnea, or when home test results are unclear or inconsistent.
Are GLP-1 drugs like tirzepatide recommended for sleep apnea in Europe?
Tirzepatide gained EMA approval for moderate-to-severe OSA in adults with obesity after trial data showed roughly 27 to 30 fewer apnea events per hour at 52 weeks (SURMOUNT-OSA, 2024). It is not a treatment for mild OSA, not a cure for snoring, and complements rather than replaces severity-based care.
What AHI level counts as mild, moderate, and severe sleep apnea?
Severity is graded by the apnea-hypopnea index, the average breathing pauses per hour. An AHI of 5 to 14 is mild, 15 to 29 is moderate, and 30 or more is severe. Fewer than 5 is considered normal. Symptoms, blood pressure, and heart health also influence which treatment is recommended.
What non-CPAP treatment options does the ERS recommend for sleep apnea?
The ERS reviewed mandibular advancement devices, positional therapy, myofunctional (tongue and throat) exercises, bariatric surgery, hypoglossal nerve stimulation, maxillo-mandibular surgery, and carbonic anhydrase inhibitors. Mandibular advancement devices are recommended for mild-to-moderate OSA and CPAP-intolerant patients, reducing AHI and daytime sleepiness versus placebo (European Respiratory Review, 2021).
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.